Cardiovascular risk markers compared across groups
| Variable | Active RA (n=82) | RA in remission (n=31) | Population controls (n=86) | p Value (active vs remission) | p Value (active vs control) | p Value (remission vs control) |
|---|---|---|---|---|---|---|
| Soluble biomarkers | ||||||
| CRP (mg/l) | 8.65 (1.49) | 5.35 (2.30) | 3.13 (1.39) | 0.001 | <0.000 | 0.09 |
| Total cholesterol (mmol/l) | 5.22 (0.13) | 5.77 (.20) | 5.84 (0.12) | 0.02 | <0.000 | 0.77 |
| HDL cholesterol (mmol/l) | 1.60 (0.06) | 1.61 (0.09) | 1.72 (0.06) | 0.90 | 0.14 | 0.33 |
| Atherogenic index | 3.58 (0.13) | 3.81 (0.20) | 3.67 (0.12) | 0.23 | 0.17 | 0.24 |
| lnNT-proBNP (pmol/l) | 2.09 (0.11) | 1.99 (0.17) | 2.09 (0.11) | 0.04 | 0.04 | 0.61 |
| Peripheral biomarkers | ||||||
| RHI | 2.02 (0.07) | 2.60 (0.11) | 2.13 (0.07) | <0.000 | 0.29 | <0.000 |
| Brachial systolic pressure (mm Hg) | 134.47 (2.01) | 126.47 (3.07) | 127.34 (1.85) | 0.03 | 0.01 | 0.81 |
| Central biomarkers | ||||||
| PWV (m/s) | 8.09 (0.16) | 7.31 (0.23) | 7.84 (0.14) | 0.003 | 0.21 | 0.05 |
| AIx | 22.57 (1.05) | 18.35 (1.53) | 18.20 (0.95) | 0.02 | 0.002 | 0.93 |
| Central systolic pressure (mm Hg) | 124.64 (1.94) | 116.20 (2.85) | 117.33 (1.77) | 0.01 | 0.005 | 0.74 |
| IMT (mm) | 0.76 (0.02) | 0.73 (0.03) | 0.74 (0.02) | 0.38 | 0.45 | 0.75 |
| Composite risk score | ||||||
| Framingham | 10.93 (0.64) | 10.11 (0.90) | 10.15 (0.53) | 0.44 | 0.34 | 0.97 |
| SCORE | 3.38 (0.27) | 2.46 (0.38) | 2.88 (0.23) | 0.04 | 0.15 | 0.34 |
Estimated marginal mean (SE) presented with adjustments for age and sex.
AIx, augmentation index; BMI, body mass index; CRP, high sensitivity C reactive protein; Framingham, Framingham risk score; HDL cholesterol, high density lipoprotein; IMT, intima-median thickness; lnNT-proBNP, natural logarithm of N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity; RHI, reactive hyperaemia index; SCORE, European Society of Cardiology SCORE risk calculator.